دورية أكاديمية
أعرض في EDS

Bacopa monnieri ameliorates memory deficits in olfactory bulbectomized mice: possible involvement of glutamatergic and cholinergic systems.

التفاصيل البيبلوغرافية
العنوان: Bacopa monnieri ameliorates memory deficits in olfactory bulbectomized mice: possible involvement of glutamatergic and cholinergic systems.
المؤلفون: Le XT; Division of Medicinal Pharmacology, Institute of Natural Medicine, University of Toyama, 2630 Sugitani, Toyama, 930-0194, Japan., Pham HT, Do PT, Fujiwara H, Tanaka K, Li F, Van Nguyen T, Nguyen KM, Matsumoto K
المصدر: Neurochemical research [Neurochem Res] 2013 Oct; Vol. 38 (10), pp. 2201-15. Date of Electronic Publication: 2013 Aug 15.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Kluwer Academic/Plenum Publishers Country of Publication: United States NLM ID: 7613461 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-6903 (Electronic) Linking ISSN: 03643190 NLM ISO Abbreviation: Neurochem Res Subsets: MEDLINE
أسماء مطبوعة: Publication: 1999- : New York, NY : Kluwer Academic/Plenum Publishers
Original Publication: New York, Plenum Press
مواضيع طبية MeSH: Bacopa/*chemistry , Memory Disorders/*drug therapy , Olfactory Bulb/*physiology , Plant Extracts/*therapeutic use, Acetylcholinesterase/metabolism ; Acoustic Stimulation ; Animals ; Choline O-Acetyltransferase/biosynthesis ; Choline O-Acetyltransferase/metabolism ; Fear ; Male ; Maze Learning/drug effects ; Mice ; Neuronal Plasticity/drug effects ; Phytotherapy ; Scopolamine/pharmacology ; Signal Transduction/drug effects
مستخلص: This study investigated the effects of alcoholic extract of Bacopa monnieri (L.) Wettst. (BM) on cognitive deficits using olfactory bulbectomized (OBX) mice and the underlying molecular mechanisms of its action. OBX mice were treated daily with BM (50 mg/kg, p.o.) or a reference drug, tacrine (2.5 mg/kg, i.p.), 1 week before and continuously 3 days after OBX. Cognitive performance of the animals was analyzed by the novel object recognition test, modified Y maze test, and fear conditioning test. Brain tissues of OBX animals were used for neurochemical and immunohistochemical studies. OBX impaired non-spatial short-term memory, spatial working memory, and long-term fair memory. BM administration ameliorated these memory disturbances. The effect of BM on short-term memory deficits was abolished by a muscarinic receptor antagonist, scopolamine. OBX downregulated phosphorylation of synaptic plasticity-related signaling proteins: NR1 subunit of N-methyl-D-aspartate receptor, glutamate receptor 1 (GluR1), and calmodulin-dependent kinase II but not cyclic AMP-responsive element binding protein (CREB), and reduced brain-derived neurotrophic factor (BDNF) mRNA in the hippocampus. OBX also reduced choline acetyltransferase in the hippocampus and cholinergic neurons in the medial septum, and enlarged the size of lateral ventricle. BM administration reversed these OBX-induced neurochemical and histological alterations, except the decrease of GluR1 phosphorylation, and enhanced CREB phosphorylation. Moreover, BM treatment inhibited ex vivo activity of acetylcholinesterase in the brain. These results indicate that BM treatment ameliorates OBX-induced cognition dysfunction via a mechanism involving enhancement of synaptic plasticity-related signaling and BDNF transcription and protection of cholinergic systems from OBX-induced neuronal damage.
References: J Neurochem. 2004 Feb;88(3):564-75. (PMID: 14720206)
J Neurol Sci. 2009 Sep 15;284(1-2):124-8. (PMID: 19439326)
Nat Rev Neurosci. 2008 Jan;9(1):65-75. (PMID: 18094707)
J Pharmacol Sci. 2007 Apr;103(4):360-73. (PMID: 17409635)
Chem Senses. 2010 Nov;35(9):855-62. (PMID: 20870956)
Annu Rev Biochem. 1999;68:821-61. (PMID: 10872467)
Cogn Process. 2012 May;13(2):93-110. (PMID: 22160349)
J Physiol. 1996 Apr 15;492 ( Pt 2):479-93. (PMID: 9019544)
J Neurosci. 2003 Feb 15;23(4):1517-23. (PMID: 12598640)
Indian J Exp Biol. 2010 Mar;48(3):306-13. (PMID: 21046986)
Neuropsychopharmacology. 2005 Dec;30(12):2135-43. (PMID: 15956997)
Behav Brain Res. 2011 Aug 10;221(2):505-14. (PMID: 21130117)
Lancet Neurol. 2010 Jul;9(7):702-16. (PMID: 20610346)
Brain. 2006 Jul;129(Pt 7):1659-73. (PMID: 16672292)
Pharmacol Biochem Behav. 2010 Dec;97(2):192-7. (PMID: 20678517)
Neuroscience. 2007 Feb 9;144(3):825-33. (PMID: 17161914)
Behav Brain Res. 2009 Aug 12;201(2):311-7. (PMID: 19428650)
Neuropharmacology. 2007 Sep;53(3):362-8. (PMID: 17644144)
Behav Neurosci. 1992 Apr;106(2):274-85. (PMID: 1590953)
Neurochem Res. 2008 Sep;33(9):1663-71. (PMID: 17940877)
Learn Mem. 2008 Feb 19;15(3):97-105. (PMID: 18285468)
Biochemistry (Mosc). 2004 Feb;69(2):176-80. (PMID: 15000684)
Eur J Neurosci. 2008 Dec;28(11):2278-87. (PMID: 19046371)
Clinics (Sao Paulo). 2011;66(4):663-71. (PMID: 21655763)
Physiol Behav. 1999 Aug 1;67(1):41-7. (PMID: 10463627)
Nature. 1993 Jan 7;361(6407):31-9. (PMID: 8421494)
Evid Based Complement Alternat Med. 2013;2013:701956. (PMID: 23573147)
Eur J Pharmacol. 2013 Jan 15;699(1-3):150-9. (PMID: 23220711)
J Ethnopharmacol. 2003 Dec;89(2-3):261-4. (PMID: 14611889)
Bratisl Lek Listy. 2011;112(12):663-9. (PMID: 22372329)
Behav Brain Res. 2013 Feb 1;238:146-53. (PMID: 23103401)
Proc Natl Acad Sci U S A. 2005 Mar 8;102(10):3811-6. (PMID: 15728733)
J Neurosci. 2010 Jan 13;30(2):505-14. (PMID: 20071513)
J Alzheimers Dis. 2010;22(4):1081-7. (PMID: 20930316)
Neurochem Res. 2012 Sep;37(9):1928-37. (PMID: 22700087)
J Altern Complement Med. 2010 Jul;16(7):753-9. (PMID: 20590480)
Biochem Pharmacol. 1961 Jul;7:88-95. (PMID: 13726518)
J Clin Exp Neuropsychol. 2010 Apr;32(4):350-7. (PMID: 19787522)
Behav Brain Res. 2003 Jan 6;138(1):9-15. (PMID: 12493626)
Neuroscience. 2009 Apr 21;160(1):149-55. (PMID: 19409205)
Evid Based Complement Alternat Med. 2012;2012:606424. (PMID: 23320031)
Behav Brain Res. 2013 Apr 1;242:150-7. (PMID: 23295391)
Brain Res. 2000 Oct 20;881(1):28-36. (PMID: 11033090)
Life Sci. 2013 Feb 7;92(2):119-24. (PMID: 23159642)
Neurobiol Learn Mem. 2000 Jan;73(1):31-48. (PMID: 10686122)
Chin Med. 2011 Sep 23;6:33. (PMID: 21943225)
J Neurochem. 2006 Apr;97(1):22-9. (PMID: 16515554)
J Pharmacol Sci. 2011;117(4):230-42. (PMID: 22083044)
Neurochem Res. 2011 Jan;36(1):7-16. (PMID: 20821261)
Brain Res. 2009 Apr 10;1265:205-14. (PMID: 19233146)
J Mass Spectrom. 2010 Jul;45(7):703-14. (PMID: 20623627)
J Ethnopharmacol. 2011 Jun 1;135(3):737-46. (PMID: 21513784)
Psychopharmacology (Berl). 2013 May;227(2):299-306. (PMID: 23354535)
BMC Complement Altern Med. 2012 Oct 20;12:188. (PMID: 23082896)
Neuropeptides. 2012 Dec;46(6):329-34. (PMID: 23103057)
Neuron. 1996 Jun;16(6):1179-88. (PMID: 8663994)
Neurosci Lett. 1990 Nov 13;119(2):207-10. (PMID: 2280895)
Cell Mol Life Sci. 1999 Apr;55(4):554-63. (PMID: 10357226)
J Pharmacol Toxicol Methods. 2006 Sep-Oct;54(2):99-105. (PMID: 16750402)
المشرفين على المادة: 0 (Plant Extracts)
DL48G20X8X (Scopolamine)
EC 2.3.1.6 (Choline O-Acetyltransferase)
EC 3.1.1.7 (Acetylcholinesterase)
تواريخ الأحداث: Date Created: 20130817 Date Completed: 20140328 Latest Revision: 20211021
رمز التحديث: 20231215
DOI: 10.1007/s11064-013-1129-6
PMID: 23949198
قاعدة البيانات: MEDLINE
الوصف
تدمد:1573-6903
DOI:10.1007/s11064-013-1129-6